Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …

The treatment of multiple myeloma has evolved significantly over the past 2 decades due to
the use of high-dose chemotherapy and autologous stem cell transplantation, and the …

Multiple myeloma is a hematologic malignancy characterized by plasma cell clonal
expansion as well as end‐organ damage due to increased levels of monoclonal proteins in …

Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM),
with safety profiles varying across drug classes and across agents within the same class …

The development of bortezomib and immunomodulatory agents resulted in a revolution in
the treatment of multiple myeloma (MM). Moreover, second-generation proteasome …

Introduction: Treatment of multiple myeloma has undergone profound changes in the past
years thanks to the increased understanding of the biology of the disease and the new …

Multiple myeloma (MM) is a clonal plasma cell malignancy clinically characterized by
osteolytic lesions, immunodeficiency, and renal disease. There are an estimated 750,000 …

Effective therapy for multiple myeloma has existed for a little more than the last half century.
The introduction of melphalan 55 years ago was followed by a stagnant period of four …

In the past few years, multiple targeted therapies and immunotherapies including second
generation immunomodulatory drugs (pomalidomide) and proteasome inhibitors …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …